Liver Disease Caused by Anesthetics, Toxins, and Herbal Preparations

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 1447-1459

  Lewis, James H ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649872812     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00087-1     Document Type: Chapter

References (171)

1. Chitturi S., Farrell GC Hepatotoxic slimming agents and other herbal hepatotoxins J Gastroenterol Hepatol 23 2008 366-373(Ref 5.)
2. Chojkier M Hepatic sinusoidal-obstruction syndrome: Toxicity of pyrrolizidine alkaloids J Hepatol 39 2003 437-446(Ref 116.)
3. Elinav E., Pinsker G., Safadi R., et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity J Hepatol 47 2007 514-520(Ref 140.)
4. Faust TW., Reddy KR Postoperative jaundice Clin Liver Dis 8 2004 151-166(Ref 33.)
5. Favreau JT., Ryu ML., Braunstein G., et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix Ann Intern Med 136 2002 590-595(Ref 137.)
6. Foti RS., Dickmann LJ., Davis JA., et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements Xenobiotica 38 2008 264-280(Ref 139.)
7. Kenna JG Mechanism, pathology, and clinical presentation of hepatotoxicity of anesthetic agents In: Kaplowitz N., DeLeve L Drug-Induced Liver Disease 2004 Marcel Dekker New York 405-424(Ref 11.)
8. Lewis JH., Kleiner D Hepatic injury due to drugs, chemicals and toxins In: Burt AD., Portmann BC., Ferrell LD MacSween’s Pathology of the Liver5th ed 2007 Churchill Livingstone Elsevier Philadelphia 649-759(Ref 37.)
9. Mandibusan MK., Odin M., Eatmond DA Postulated carbon tetrachloride mode of action: A review J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25 2007 185-209(Ref 38.)
10. Mohi-ud-din R., Lewis JH Drug-and chemical-induced cholestasis Clin Liver Dis 8 2004 95-132(Ref 93.)
11. Rengstorff DS., Osorio RW., Bonacini M Recovery from severe hepatitis caused by mushroom poisoning without liver transplantation Clin Gastroenterol Hepatol 1 2003 392-396(Ref 89.)
12. Schoepfer AM., Engel A., Fattinger K., et al. Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products J Hepatol 47 2007 521-526(Ref 141.)
13. Seeff LB., Lindsay KL., Bacon BR., et al. Complementary and alternative medicine in chronic liver disease Hepatology 34 2001 595-603(Ref 98.)
14. Verma S., Thuluvath PJ Complementary and alternative medicine in hepatology: Review of evidence of efficacy Clin Gastroenterol Hepatol 5 2007 408-416(Ref 99.)
15. Zimmerman HJ Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver2nd ed 1999 Lippincott Williams & Wilkins Philadelphia(Ref 1.)
16. Zimmerman HJ., Lewis JH Chemical-and toxin-induced hepatotoxicity Gastroenterol Clin North Am 24 1995 1027-1045(Ref 3.)
17. Zimmerman HJ Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver2nd ed 1999 Lippincott Williams & Wilkins Philadelphia.
18. Lewis JH Drug-induced liver disease Med Clin North Am 84 2000 1275-1311.
19. Zimmerman HJ., Lewis JH Chemical-and toxin-induced hepatotoxicity Gastroenterol Clin North Am 24 1995 1027-1045.
20. Tolman KG., Sirrine RW Occupational hepatotoxicity Clin Liver Dis 2 1998 563-589.
21. Chitturi S., Farrell GC Hepatotoxic slimming agents and other herbal hepatotoxins J Gastroenterol Hepatol 23 2008 366-373.
22. Schiano TD Hepatotoxicity and complementary and alternative medicines Clin Liver Dis 7 2003 453-473.
23. Mindikoglu AL., Magder LS., Regev A Outcome of liver transplantation for drug-induced acute liver failure in the United States: Analysis of the United Network for Organ Sharing database Liver Transplant 15 2009 719-729.
24. Weber LW., Boll M., Stampfl A Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model Crit Rev Toxicol 33 2003 105-136.
25. Inman WH., Mushin WW Jaundice after repeated exposure to halothane: A further analysis of reports to the Committee on Safety of Medicines BMJ 2 1978 1455-1456.
26. Holt C., Csete M., Martin P Hepatotoxicity of anesthetics and other central nervous system drugs Gastroenterol Clin North Am 24 1995 853-874.
27. Kenna JG Mechanism, pathology, and clinical presentation of hepatotoxicity of anesthetic agents In: Kaplowitz N., DeLeve L Drug-Induced Liver Disease 2004 Marcel Dekker New York 405-424.
28. Njoku D., Laster MJ., Gong DH., et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury Anesth Analg 84 1997 173-178.
29. Lo SK., Wendon J., Mieli-Vergani G., et al. Halothane-induced acute liver failure: Continuing occurrence and use of liver transplantation Eur J Gastroenterol Hepatol 10 1998 635-639.
30. Vergani D., Mieli-Vergani G., Alberti A., et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis N Engl J Med 303 1980 66-71.
31. Summary of the National Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis JAMA 197 1966 775-788.
32. Neuberger J Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines Drug Saf 5 1990 28-38.
33. Njoku DB., Greenberg RS., Bourdi M., et al. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists Anesth Analg 94 2002 243-249.
34. Sakaguchi Y., Inaba S., Irita K., et al. Absence of antitrifluoroacetate antibody after halothane anaesthesia in patients exhibiting no or mild liver damage Can J Anaesth 41 1994 398-403.
35. Cousins MJ., Plummer JL., Hall PD Risk factors for halothane hepatitis Aust N Z J Surg 59 1989 5-14.
36. Benjamin SB., Goodman ZD., Ishak KG., et al. The morphologic spectrum of halothane-induced hepatic injury: Analysis of 77 cases Hepatology 5 1985 1163-1171.
37. Martin JL., Dubbink DA., Plevak DJ., et al. Halothane hepatitis 28 years after primary exposure Anesth Analg 74 1992 605-608.
38. Spracklin DK., Emery ME., Thummel KE., et al. Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats Acta Anaesthesiol Scand 47 2003 765-770.
39. Farrell GC., Prendergast D., Murray M Halothane hepatitis. Detection of a constitutional susceptibility factor N Engl J Med 313 1985 1310-1314.
40. Unsal C., Celik JB., Toy H., et al. Protective role of zinc pretreatment in hepatotoxicity induced by halothane Eur J Anaesthesiol 2008; June 5 1-6 [Epub ahead of print].
41. Joshi PH., Conn HO The syndrome of methoxyflurane-associated hepatitis Ann Intern Med 80 1974 395-401.
42. Lewis JH., Zimmerman HJ., Ishak KG., et al. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases Ann Intern Med 98 1983 984-992.
43. Eger EI II., Smuckler EA., Ferrell LD., et al. Is enflurane hepatotoxic? Anesth Analg 65 1986 21-30.
44. Turner GB., O’Rourke D., Scott GO., et al. Fatal hepatotoxicity after re-exposure to isoflurane: A case report and review of the literature Eur J Gastroenterol Hepatol 12 2000 955-959.
45. Martin JL., Keegan MT., Vasdev GMS., et al. Fatal hepatitis associated with isoflurane exposure and CYP2A6 autoantibodies Anesthesiology 95 2001 551-553.
46. Njoku DB., Shrestha S., Soloway R., et al. Subcellular localization of trifluoroacetylated liver proteins in association with hepatitis following isoflurane Anesthesiology 96 2002 757-761.
47. Singhal S., Gray T., Grace G., et al. Sevoflurane hepatotoxicity: A case report of sevoflurane hepatic necrosis and review of the literature Am J Ther 2009 [Epub ahead of print].
48. Turillazzi E., D’Errico S., Neri M., et al. A fatal case of fulminant hepatic necrosis following sevoflurane anesthesia Toxicol Pathol 35 2007 840-845.
49. Faust TW., Reddy KR Postoperative jaundice Clin Liver Dis 8 2004 151-166.
50. National Institute for Occupational Safety and Health (NIOSH) Pocket Guide to Chemical Hazards September 2007 DHHS Publication No. 2005-149. Government Printing Office, P.O. Box 371954, Pittsburgh, PA 15250-7954www.cdc.gov/niosh/npg/npg.html.
51. Wexler P The U.S. National Library of Medicine’s Toxicology and Environmental Health Information Program Toxicology 198 2004 161-168.
52. Lewis JH., Zimmerman HJ Drug-and chemical-induced cholestasis Clin Liver Dis 3 1999 433-464.
53. Lewis JH., Kleiner D Hepatic injury due to drugs, chemicals and toxins In: Burt AD., Portmann BC., Ferrell LD MacSween’s Pathology of the Liver5th ed 2007 Churchill Livingstone Elsevier Philadelphia 649-759.
54. Mandibusan MK., Odin M., Eatmond DA Postulated carbon tetrachloride mode of action: A review J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25 2007 185-209.
55. Croquet V., Fort J., Oberti F., et al. 1, 1, 1-trichloroethane-induced chronic active hepatitis Gastroenterol Clin Biol 27 2003 120-122.
56. Boucher R., Hanna C., Rusch GM., et al. Hepatotoxicity associated with overexposure to 1, 1-dichloro-2, 2, 2-trifluoroethane (HCFC-123) AIHA J (Fairfax, Va) 64 2003 68-79.
57. Hoet P., Buchet JP., Sempoux C., et al. Potentiation of 2, 2-dichloro-1, 1, 1-trifluoroethane (HCFC-123)-induced liver toxicity by ethanol in guinea pigs Arch Toxicol 76 2002 707-714.
58. Cave MC., Mahalingashetty A., Khan R., et al. Non-alcoholic fatty liver disease in non-obese American chemical workers Hepatology 46 4 suppl 1 2007 746A.
59. Du CL., Wang JD Increased morbidity odds ratio of primary liver cancer and cirrhosis of the liver among vinyl chloride monomer workers Occup Environ Med 55 1998 528-532.
60. Maroni M., Mocci F., Visentin S., et al. Periportal fibrosis and the liver ultrasonography findings in vinyl chloride workers Occup Environ Med 60 2003 60-65.
61. Cave MC., Groce R., Mahalingashetty A., et al. Elevated serum hyaluronic acid may identify vinyl chloride workers at high risk for the subsequent development of hepatic angiosarcoma Hepatology 46 4 suppl 1 2007 427A.
62. Meadows R., Verghese A Medical complications of glue sniffing South Med J 89 1996 455-462.
63. Aydin Y., Ozcakar L Occupational hepatitis due to chronic inhalation of propane and butane gases Int J Clin Pract 57 2003 546.
64. Senoh H., Katagiri T., Arito H., et al. Toxicity due to 2-and 13-wk inhalation exposures of rats and mice to N, N-dimethylformamide J Occup Health 45 2003 365-375.
65. Fiorito A., Larese F., Molinari S., et al. Liver function alterations in synthetic leather workers exposed to dimethylformamide Am J Ind Med 32 1997 255-260.
66. Luo JC., Kuo HW., Cheng TJ., et al. Abnormal liver function associated with occupational exposure to dimethylformamide and hepatitis B virus J Occup Environ Med 43 2001 474-482.
67. Kao YH., Chong CH., Ng WT., et al. Hydrazine inhalation hepatotoxicity Occup Med (Lond) 57 2007 535-537.
68. Singh N., Jatav OP., Gupta RK., et al. Outcome of sixty four cases of ethylene bromide ingestion treated in a tertiary care hospital J Assoc Physicians India 55 2007 842-845.
69. Niittynen M., Tuomisto JT., Auriola S., et al. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD)-induced accumulation of biliverdin and hepatic peliosis in rats Toxicol Sci 71 2003 112-113.
70. Michalek JE., Ketchum NS., Longnecker MP Serum dioxin and hepatic abnormalities in veterans of Operation Ranch Hand Ann Epidemiol 11 2001 304-311.
71. Tamburro CH Chronic liver injury in phenoxy herbicide-exposed Vietnam veterans Environ Res 59 1992 175-188.
72. Cordier S., Le TB., Verger P., et al. Viral infections and chemical exposures as risk factors for hepatocellular carcinoma in Vietnam Int J Cancer 55 1993 196-201.
73. Botella de Maglia J., Belenguer Tarin JE Paraquat poisoning. A study of 29 cases and evaluation of the effectiveness of the “Caribbean scheme.” Med Clin (Barc) 115 2000 530-533.
74. Mullick FG., Ishak KG., Mahabir R., et al. Hepatic injury associated with paraquat toxicity in humans Liver 1 1981 209-221.
75. Carpenter HM., Hedstrom OR., Siddens LK., et al. Ultrastructural, protein, and lipid changes in liver associated with chlordecone treatment of mice Fundam Appl Toxicol 34 1996 157-164.
76. Santra A., Das Gupta J., De BK., et al. Hepatic manifestations in chronic arsenic toxicity Indian J Gastroenterol 18 1999 152-155.
77. Eisler R Arsenic hazards to humans, plants, and animals from gold mining Rev Environ Contam Toxicol 180 2004 133-165.
78. Rice KC., Conko KM., Hornberger GM Anthropogenic sources of arsenic and copper to sediments in a suburban lake, Northern Virginia Environ Sci Technol 36 2002 4962-4967.
79. Guha Mazumder DN Chronic arsenic toxicity: Clinical features, epidemiology, and treatment: Experience in West Bengal J Environ Sci Health A Tox Hazard Subst Environ Eng 38 2003 141-163.
80. Chen Y., Ahsan H Cancer burden from arsenic in drinking water in Bangladesh Am J Public Health 94 2004 741-744.
81. Kannan GM., Flora SJ Chronic arsenic poisoning in the rat: Treatment with combined administration of succimers and an antioxidant Ecotoxicol Environ Saf 58 2004 37-43.
82. Robertson A., Tenenbein M Hepatotoxicity in acute iron poisoning Hum Exp Toxicol 24 2005 559-562.
83. Britton RS Metal-induced hepatotoxicity Semin Liver Dis 16 1996 3-12.
84. Olivieri NF., Brittenham GM., McLaren CE., et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major N Engl J Med 339 1998 417-423.
85. Wanless IR., Sweeney G., Dhillon AP., et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia Blood 100 2002 1566-1569.
86. Ito Y., Kojiro N., Nakashima T., et al. Pathomorphologic characteristics of 102 cases of Thorotrast-related hepatocellular carcinoma, cholangiocarcinoma and hepatic angiosarcoma Cancer 62 1988 1153-1162.
87. Newairy AA., El-Sharaky AS., Badreideen MM., et al. The hepatoprotective effects of selenium against cadmium toxicity in rats Toxicology 242 2007 23-30.
88. Rana SV. Metals and apoptosis: Recent developments J Trace Elem Med Biol 22 2008 262-284.
89. Johri S., Shukla S., Sharma P Role of chelating agents and antioxidants in beryllium induced toxicity Indian J Exp Biol 40 2002 575-582.
90. Mudipalli A Lead hepatotoxicity and potential health effects Indian J Med Res 126 2007 518-527.
91. Sanchez-Porro Valades P., Posada de la Paz M., de Andres Copa P., et al. Toxic oil syndrome: Survival in the whole cohort between 1981 and 1995 J Clin Epidemiol 56 2003 701-708.
92. Hall AJ., Harrington JM., Waterhouse JA The Epping jaundice outbreak: A 24 year follow up J Epidemiol Community Health 46 1992 327-328.
93. Yoshimura T Yusho in Japan Ind Health 41 2003 139-148.
94. Silva MO., Roth D., Reddy KR., et al. Hepatic dysfunction accompanying acute cocaine intoxication J Hepatol 12 1991 312-315.
95. Aoki K., Takimoto M., Ota H., et al. Participation of CYP2A in cocaine-induced hepatotoxicity in female mice Pharmacol Toxicol 87 2000 26-32.
96. Labib R., Abdel-Rahman MS., Turkall R N-acetylcysteine pretreatment decreases cocaine-and endotoxin-induced hepatotoxicity J Toxicol Environ Health A 66 2003 223-239.
97. Henry JA., Jeffreys KJ., Dawling S Toxicity and deaths from 3, 4-methylenedioxymethamphetamine (“ecstasy”) Lancet 340 1992 384-387.
98. Garbino J., Henry JA., Mentha G., et al. Ecstasy ingestion and fulminant hepatic failure: Liver transplantation to be considered as a last therapeutic option Vet Human Toxicol 43 2001 99-102.
99. Lange-Brock N., Berg T., Muller AR., et al. Acute liver failure following the use of ecstasy (MDMA) Z Gastroenterol 40 2002 581-586.
100. Maurer HH., Kraemer T., Springer D., et al. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: A synopsis Ther Drug Monit 26 2004 127-131.
101. Armen R., Kanel G., Reynolds T Phencyclidine-induced malignant hyperthermia causing submassive liver necrosis Am J Med 77 1984 167-172.
102. Litovitz L., Klein-Schwartz W., Rodgers GC., et al. 2001 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System Am J Emerg Med 20 2002 391-452.
103. Nordt SP., Manoguerra A., Clark RF 5-year analysis of mushroom exposures in California West J Med 173 2000 314-317.
104. Vetter J Toxins of Amanita phalloides Toxicon 36 1998 13-24.
105. Rengstorff DS., Osorio RW., Bonacini M Recovery from severe hepatitis caused by mushroom poisoning without liver transplantation Clin Gastroenterol Hepatol 1 2003 392-396.
106. Broussard CN., Aggarwal A., Lacey SR., et al. Mushroom poisoning-from diarrhea to liver transplantation Am J Gastroenterol 96 2001 3195-3198.
107. Enjalbert F., Rapior S., Nouguier-Soule J., et al. Treatment of amatoxin poisoning: 20-Year retrospective analysis J Toxicol Clin Toxicol 40 2002 715-757.
108. Toxic hypoglycemic syndrome-Jamaica, 1989-1991 MMWR Morb Mortal Wkly Rep 41 1992 53-55.
109. Mohi-ud-din R., Lewis JH Drug-and chemical-induced cholestasis Clin Liver Dis 8 2004 95-132.
110. Angsubhakorn S., Pradermwong A., Phanwichien K., et al. Promotion of aflatoxin B1-induced hepatocarcinogenesis by dichlorodiphenyl trichloroethane (DDT) Southeast Asian J Trop Med Public Health 33 2002 613-623.
111. Kew MC Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis Liver Int 23 2003 405-409.
112. Rhee SM., Garg VK., Hershey CO Use of complementary and alternative medicines by ambulatory patients Arch Intern Med 164 2004 1004-1009.
113. Eisenberg DM., Kessler RC., Van Rompay MI Perceptions about complementary therapies relative to conventional therapies among adults who use both. Results from a national survey Ann Intern Med 135 2001 344-351.
114. Seeff LB., Lindsay KL., Bacon BR., et al. Complementary and alternative medicine in chronic liver disease Hepatology 34 2001 595-603.
115. Verma S., Thuluvath PJ Complementary and alternative medicine in hepatology: Review of evidence of efficacy Clin Gastroenterol Hepatol 5 2007 408-416.
116. Angell M., Kassirer JP Alternative medicine-the risks of untested and unregulated remedies N Engl J Med 339 1998 839-841.
117. Estes JD., Stolpman D., Olyaei A., et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure Arch Surg 138 2003 852-858.
118. Stickel F., Egerer G., Seitz HK Hepatotoxicity of botanicals Public Health Nutr 3 2000 113-124.
119. Kafrouni MI., Anders RA., Verma S Hepatotoxicity associated with dietary supplements containing anabolic steroids Clin Gastroenterol Hepatol 5 2007 809-812.
120. Shah NL., Zacharias I., Khettry U., et al. Methasteron-associated cholestatic liver injury: Clinicopathologic findings in 5 cases Clin Gastroenterol Hepatol 6 2008 255-258.
121. Geubel AP., De Galocsy C., Alves N., et al. Liver damage caused by therapeutic vitamin A administration: Estimation of dose-related toxicity in 41 cases Gastroenterology 100 1991 1701-1709.
122. Leo MA., Lieber CS Hypervitaminosis A. A liver lover’s lament Hepatology 8 1988 412-417.
123. Kowalski TE., Falestiny M., Furth E., et al. Vitamin A hepatotoxicity: A cautionary note regarding 25, 000 IU supplements Am J Med 97 1994 523-528.
124. Johnson EJ., Krall EA., Dawson-Hughes B., et al. Lack of an effect of multivitamins containing vitamin A on serum retinyl esters and liver function tests in healthy women J Am Coll Nutr 11 1992 682-686.
125. Jorens PG., Michielsen PP., Pelckmans PA., et al. Vitamin A abuse: Development of cirrhosis despite cessation of vitamin A. A six-year clinical and histopathologic follow-up Liver 12 1992 381-386.
126. Sarles J., Scheiner C., Sarran M., et al. Hepatic hypervitaminosis A: A familial observation J Pediatr Gastroenterol Nutr 10 1990 71-76.
127. Myhre AM., Carlsen MH., Bohn SK., et al. Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations Am J Clin Nutr 78 2003 1152-1159.
128. Hautekeete ML., Geerts A The hepatic stellate (Ito) cell: Its role in human liver disease Virchows Arch 430 1997 195-207.
129. Leo MA., Lieber CS Alcohol, vitamin A, and β-carotene: Adverse interactions, including hepatotoxicity and carcinogenicity Am J Clin Nutr 69 1999 1071-1085.
130. Ukleja A., Scolapio JS., McConnell JP., et al. Nutritional assessment of serum and hepatic vitamin A levels in patients with cirrhosis JPEN J Parenter Enteral Nutr 26 2002 184-188.
131. Leithead JA., Simpson KJ., MacGilchrist AJ Fulminant hepatic failure following overdose of the vitamin A metabolite acitretin Eur J Gastroenterol Hepatol 21 2009 230-232.
132. Chojkier M Hepatic sinusoidal-obstruction syndrome: Toxicity of pyrrolizidine alkaloids J Hepatol 39 2003 437-446.
133. Copple BL., Ganey PE., Roth RA Liver inflammation during monocrotaline hepatotoxicity Toxicology 190 2003 155-169.
134. Perez Alvarez J., Saez-Royuela F., Gento Pena E., et al. Acute hepatitis due to ingestion of Teucrium chamaedrys infusions Gastroenterol Hepatol 24 2001 240-243.
135. Larrey D., Vial T., Pauwels A., et al. Hepatitis after germander (Teucrium chamaedrys) administration: Another instance of herbal medicine hepatotoxicity Ann Intern Med 117 1992 129-132.
136. De Berardinis V., Moulis C., Maurice M., et al. Human microsomal epoxide hydrolase is the target of germander induced autoantibodies on the surface of human hepatocytes Mol Pharmacol 58 2000 542-551.
137. Dourakis S., Papanikolaou IS., Tzemanakis EN., et al. Acute hepatitis associated with herb (Teucrium capatatum L.) administration Eur J Gastroenterol Hepatol 14 2002 693-695.
138. Polymeros D., Kamberoglou D., Tzias V Acute cholestatic hepatitis caused by Teucrium polium (golden germander) with transient appearance of antimitochondrial antibody J Clin Gastroenterol 34 2002 100-101.
139. Sheikh NM., Philen RM., Love LA Chaparral-associated hepatotoxicity Arch Intern Med 157 1997 913-919.
140. Anderson IB., Mullen WH., Meeker JE., et al. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature Ann Intern Med 124 1996 726-734.
141. Sztajnkrycer MD., Otten EJ., Bond GR., et al. Mitigation of pennyroyal oil hepatotoxicity in the mouse Acad Emerg Med 10 2003 1024-1028.
142. Woolf GM., Petrovic LM., Rojter SE., et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan Ann Intern Med 121 1994 729-735.
143. Horowitz RS., Feldhaus K., Dart RC., et al. The clinical spectrum of jin bu huan toxicity Arch Intern Med 156 1996 899-903.
144. Itoh S., Marutani K., Nishijima T., et al. Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang) Dig Dis Sci 40 1995 1845-1848.
145. Kamiyama T., Nouchi T., Kojima S., et al. Autoimmune hepatitis triggered by administration of an herbal medicine Am J Gastroenterol 92 1997 703-704.
146. Mazzanti G., Battinelli L., Daniele C., et al. New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum Ann Intern Med 140 2004 W30.
147. Nadir A., Agarwal S., King PD., et al. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang Am J Gastroenterol 91 1996 1436-1438.
148. Bajaj J., Know JF., Komorowski R., et al. The irony of herbal hepatitis: Ma-huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis Dig Dis Sci 48 2003 1925-1928.
149. Shekelle PG., Hardy ML., Morton SC., et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: A meta-analysis JAMA 289 2003 1537-1545.
150. Rados C Ephedra ban: No shortage of reasons FDA Consumer 38 2004 6.
151. Adachi M., Saito H., Kobayashi H., et al. Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido Ann Intern Med 139 2003 488-492.
152. Kawaguchi T., Harada M., Arimatsu H., et al. Severe hepatotoxicity associated with a N-nitrosofenfluramine-containing weight-loss supplement: Report of three cases J Gastroenterol Hepatol 19 2004 349-350.
153. Favreau JT., Ryu ML., Braunstein G., et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix Ann Intern Med 136 2002 590-595.
154. Durazo FA., Lassman C., Han SHB., et al. Fulminant liver failure due to usnic acid for weight loss Am J Gastroenterol 99 2004 950-952.
155. Foti RS., Dickmann LJ., Davis JA., et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements Xenobiotica 38 2008 264-280.
156. Elinav E., Pinsker G., Safadi R., et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity J Hepatol 47 2007 514-520.
157. Schoepfer AM., Engel A., Fattinger K., et al. Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products J Hepatol 47 2007 521-526.
158. Dara L., Hewett J., Lim JK Hydroxycut hepatotoxicity: A case series and review of liver toxicity from herbal weight loss supplements World J Gastroenterol 14 2008 6999-7004.
159. Schneider C., Segre T Green tea: Potential health benefits Am Fam Physician 79 2009 591-594.
160. Mazzanti G., Menniti-Ippolito F., Moro PA., et al. Hepatotoxicity from green tea: A review of the literature and two unpublished cases Eur J Clin Pharmacol 65 2009 331-341.
161. Sarma DN., Barrett ML., Chavez ML., et al. Safety of green tea extracts: A systematic review by the US Pharmacopeia Drug Saf 31 2008 469-484.
162. Liss G., Lewis JH Drug-induced liver injury: What was new in 2008? Expert Opin Drug Metab Toxicol 5 2009 1-18.
163. Schulze J., Raasch W., Siegers CP Toxicity of kava pyrones, drug safety and precautions-a case study Phytomedicine 10 suppl 4 2003 68-73.
164. Stickel F., Baumuller HM., Seitz K., et al. Hepatitis induced by kava (Piper methysticum rhizome) J Hepatol 39 2003 62-67.
165. Clouatre DL Kava kava: Examining new reports of toxicity Toxicol Lett 150 2004 85-96.
166. Teschke R., Schwarzenboeck A., Hennermann KH Kava hepatotoxicity: A clinical survey and critical analysis of 26 suspected cases Eur J Gastroenterol Hepatol 20 2008 1182-1193.
167. Teschke R., Schwartzenboeck A., Akinci A Kava hepatotoxicity: A European view N Z Med J 121 2008 90-98.
168. Nerurkar PV., Dragull K., Tang CS In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones Toxicol Sci 79 2004 106-111.
169. Lude S., Torok M., Dieterle S., et al. Hepatocellular toxicity of kava leaf and root extracts Phytomedicine 15 2008 120-131.
170. Mahady GB., Low Dog T., Barrett ML., et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity Menaopause 15 4 pt 1 2008 628-638.
171. Teschke R., Bahre R., Genthner A., et al. Suspected black cohosh hepatotoxity-challenges and pitfalls of causality assessment Maturitas 63 2009 302-314.